Analysis of HER2 testing in breast cancer: disparities, cost-effectiveness, and patterns of care by Ashok, Mahima
ANALYSIS OF HER2 TESTING IN BREAST CANCER:  










A Dissertation  
Presented to  










In Partial Fulfillment 
Of the Requirements for the Degree 


















Analysis of HER2 Testing in Breast Cancer:  
































Dr. Paul Griffin, Advisor    Dr. Michael Halpern 
School of Industrial and Systems  Health, Social and Economics 
Engineering Research Division 
Georgia Institute of Technology Research Triangle Institute  
     
 
Dr. Richard Nichols     Dr. Brani Vidakovic 
School of Applied Physiology Department of Biomedical 
Georgia Institute of Technology   Engineering 
 Georgia Institute of Technology 
 
 
Dr. Robert Butera Date Approved: June 11, 2009 
School of Electrical and  
Computer Engineering 




















For Mom, my Hero, source of all Good things 
For Dad, giver of Strength 






This dissertation has been made possible because of the gracious support of so many 
people. Dr. Michael Halpern has been the most consistent and reliable mentor any PhD 
candidate can hope to have, and for this, I am immensely grateful. This work simply 
would not have been possible without his guidance. My serendipitous meeting with him 
several years ago has led me to a career that I find deeply fulfilling, and I cannot thank 
him enough for his kindness and support through the years.   
 
Dr. Paul Griffin has been a kind and thoughtful advisor, has given me the freedom to 
develop this work, and has provided critical feedback throughout the process. Through 
his role as advisor, he has helped me sharpen this work and has greatly supported my 
research at Tech. I am extremely thankful to him for his immense support during my PhD 
experience. I am fortunate to have had the opportunity to work with Dr. Griffin. 
 
I met Dr. Richard Nichols on my first day as a PhD student in the department of 
Biomedical Engineering, and it turned out to be quite lucky for me that I did. Through the 
years, I have had the honor of taking a directed study course with him, and have we 
have discussed various topics, from history and politics to research and medicine. His 
knowledge and wisdom are unparalleled, and I can only hope that some of it has rubbed 
off on me through these years.  
 
Dr. Robert Butera has been extremely supportive of my work and has been instrumental 
in giving me an academic home at Georgia Tech in the Bioengineering program. He 




support has been invaluable to me.  I am extremely thankful that he has served on my 
doctoral committee.  
 
The final member of my doctoral committee, but most certainly not the least, is Dr. Brani 
Vidakovic, who I am quite certain, is one of the nicest people I have ever had the 
pleasure of knowing. In addition, Dr. Vidakovic is a remarkable professor, and I have 
benefited greatly from his immense knowledge. I am very thankful to him for all his 
support.  
 
Special thanks are due to Ms. Sally Gerrish of the Biomedical Engineering department 
who has been a great friend and advisor to me through my years in this program. I also 
thank Erin Hamilton, my colleague in lab who has become a great friend. Erin’s 
friendship has made lab a happy place to be. 
 
I would like to thank the American Cancer Society for the data used in this research. 
  
In addition, there are some very special people I must thank. My dear family; especially 
my mom, about whom I have only the most wonderful things to say. She is really the 
most remarkable person I know, and I want to be just like her when I grow up. My 
amazing Dad: the kindest and smartest person I know – the original Dr. Ashok – whose 
love and support are immeasurable. There are so many reasons I am glad I came to this 
place, at this time, for a PhD – and the absolute best thing of all is that it led me to Karan 
–- who is exceptional and wonderful; who stands with me always, and who has brought 






Table of Contents 
 
Acknowledgements iv 
List of Tables viii 
List of Figures ix 
List of Abbreviations x 
Summary xi 
Chapter 1 1 
1. 1 Methods and Materials 3 
1.2 Results 3 
1.2.1    Variability in HER2 IHC Results based on Laboratory Characteristics and Scoring 3 
1.2.2   Variability in IHC Results among Test Antibodies 5 
1.2.3   FISH vs. IHC 6 
1.3   Discussion 13 
1.4   References 16 
Chapter 2 22 
2.1   Introduction 22 
2.2   Materials and Methods 24 
2.3   Analysis 28 
2.3.1   Preliminary Models 28 
2.3.2   Final Model 29 
2.4   Results 32 
2.5   Discussion 34 
2.5.1   Location 34 
2.5.2   Diagnosis Date 35 
2.5.3   Stage 36 
2.6   Conclusion 37 





3.1   Introduction 45 
3.2   Materials and Methods 47 
3.2.1   Preliminary Models 49 
3.2.2   Final Model 50 
3.3   Results 52 
3.4   Discussion 54 
3.5   References 60 
Chapter 4 63 
4.1   Introduction 63 
4.2   Materials and Methods 65 
4.3   Results 74 
4.3.1   Point Estimate Analysis 74 
4.3.2   Probabilistic Sensitivity Analysis 80 
4.4   Discussion 85 
4.5   References 89 















List of Tables 
 
 Page 
Table 1.1: Positive Scores in FDA Approved IHC Assays 7 
Table 2.1: Details of Data 25 
Table 2.2: Details of Clinical Practices that Contributed to Data-set 26 
Table 2.3: Final Model 29 
Table 2.4: Variables in Final Model: Factors that Affect Choice of HER2 Test 30 
Table 2.5: Logistic Regression Output 31 
Table 2.6: Goodness of Fit of the Model 32 
Table 3.1: Details of Data 47 
Table 3.2: Details of Clinical Practices that Contributed to Data-set 47 
Table 3.3: Final Model 50 
Table 3.4: Logistic Regression Output 52 
Table 3.5: Hosmer and Lemeshow Test 52 
Table 3.6a: Trastuzumab Prescription and HER2 Status Information by Location 55 
Table 3.6a: Trastuzumab Prescription for HER2 Positive Patients by Location 56 











List of Figures 
 
           Page 
Figure 4.1: No HER2 Test Scenario 69 
Figure 4.2: IHC for HER2 Testing in Breast Cancer – A Model 70 
Figure 4.3: FISH for HER2 Testing in Breast Cancer – A Model 71 
Figure 4.4a: Input Beta Distribution for IHC False Negatives 72 
Figure 4.4b: Input Beta Distribution for IHC False Positives 72 
Figure 4.5a: Input Beta Distribution for FISH False Negatives 73 
Figure 4.5b: Input Beta Distribution for FISH False Positives 73 
Figure 4.6: State Transition Model for Patients Diagnosed with Breast Cancer 74 
Figure 4.7: No Test Scenario – Expected Values 78  
Figure 4.8: IHC for HER2 Testing in Breast Cancer – Expected Values 79 
Figure 4.9: FISH for HER2 Testing in Breast Cancer – Expected Values 80 
Figure 4.10: IHC Model for Probabilistic Sensitivity Analysis 82 
Figure 4.11: FISH Model for Probabilistic Sensitivity Analysis 83 
Figure 4.12: Distribution of Outcomes for IHC Simulation (at Root Node) 85 

















HER2      Human Epidermal growth factor Receptor 2 
 
FISH      Fluorescence In Situ Hybridization 
 
IHC      Immunohistochemistry 
 
FDA      Food and Drug Administration 
 
TNM      Solid tumor staging system: T – Tumor  
      Size, N – lymph Node involvement, M –  
      Metastases 
 
NCCN      National Comprehensive Cancer Network 
 
LCIS      Lobular Carcinoma In Situ 
 
DCIS       Ductal Carcinoma In Situ 
 
QALY      Quality Adjusted Life Years 
 




















HER2 breast cancer is an aggressive disease that occurs in 20 – 30% of the breast 
cancer population. Treatment for HER2 breast cancer includes use of an anti-HER2 
monoclonal antibody, trastuzumab. Testing for HER2 is of critical importance due to the 
adverse side effects and substantial costs associated with this anti-HER2 treatment. 
Currently, two kinds of tests, Fluorescence In Situ Hybridization (FISH) and 
Immunohistochemistry (IHC), are FDA approved for determination of HER2 status in 
breast cancers.  
 
Clinical and non clinical factors that affect the choice HER2 test and the use of anti-
HER2 therapy in breast cancer were analyzed using a data set containing information 
from six outpatient oncology clinics in the United States. The analysis showed that 
geographic location, cancer stage, and diagnosis date (pre- or post-publication of testing 
guidelines) have significant effects on choice of test. With regard to trastuzumab 
prescription, geographic location and HER2 status have significant effects on the 
prescription of trastuzumab. In addition, there was a non-significant trend for certain 
Medicare patients not to receive trastuzumab therapy. These findings indicate that 
disparities are present in breast cancer care based on geography and cancer stage, and 
highlight the importance of testing guidelines. 
 
The cost effectiveness of FISH vs. IHC was determined, by considering the financial and 
health-related costs associated with testing and subsequent treatment as well as the 
accuracy of each test. The results show that FISH is the optimal choice for HER2 testing 







Fluorescence In Situ Hybridization and 
Immunohistochemistry for HER2 Status Detection in 
Breast Cancer 
 
The American Cancer Society estimates that in the United States alone, over 182,000 
women will be diagnosed with invasive breast cancer and over 40,000 women will die of 
this disease in 2008. (1) However, rates of death from breast cancer are declining, and 
the American Cancer Society attributes this to earlier detection and better treatment 
methods. Optimal breast cancer treatment involves determining the stage of disease at 
diagnosis as well as characteristics of the tumor, including estrogen and progesterone 
receptor status and HER2 overexpression.   
 
The human epidermal growth factor receptor 2, called HER2 or c-erbB-2, encodes a 
tyrosine kinase. The HER2 gene belongs to a family of genes that encode 
transmembrane receptors for growth factors. (2) Gene amplification of HER2 with 
subsequent protein overexpression has been shown to exist in 20 % to 25% of invasive 
breast cancers. (2-7) HER2 amplification and overexpression are associated with 
increased tumor aggressiveness and poor prognosis. (2, 3)  
 
Trastuzumab (Herceptin®) is a humanized monoclonal antibody indicated for treatment 
of HER2 positive breast cancer. Trastuzumab is an anti-HER2 antibody that works 
synergistically with chemotherapy in HER2 overexpressing cancer cells (7). This drug 
has significant benefits for HER2 positive breast cancer patients; however, it is 




toxicity) and with substantial costs.  Thus, to ensure appropriate use of this medication 
for breast cancer treatment, accurate testing for HER2 is of critical importance.  
 
There are currently two main types of tests used to assess levels of HER2 in breast 
cancer: Fluorescence in Situ Hybridization (FISH) and Immunohistochemistry (IHC). 
FISH measures HER2 gene amplification while IHC measures levels of the HER2 
protein. The first practical application of the FISH technique was in 1980 and the 
technology has evolved in the 20 years since that time. (8) FISH uses fluorescent DNA 
probes to identify specific parts of a chromosome; in this case the HER2 gene. The 
probe is made complementary to the sequence that is being detected and is labeled with 
a fluorescent marker to facilitate visualization using a fluorescent microscope. 
Immunohistochemistry, which has been used since the 1940s, consists of using an 
antibody to link a desired antigen to a detectable marker, such as a stain, enzyme, or 
radioactive element. This makes it easier to visualize the antigen under a microscope or 
with appropriate detectors.  In the case of HER2 detection, monoclonal or polyclonal 
anti-HER2 antibodies are used. There are currently six FDA-approved FISH and IHC 
tests for HER2 diagnosis in the United States: PathVysion (FISH, Vysis Inc.), INFORM 
(FISH, Ventana Medical Systems), FISH PharmDx (FISH, Dako), InSite (IHC, BioGenex 
Laboratories, Inc), HercepTest (IHC, Dako), and Pathway (IHC, Ventana).  
 
A number of published reviews have evaluated literature associated with HER2 testing.    
In particular, a joint report from the American Society of Clinical Oncology and the 
College of American Pathologists (9) and a report from the National Comprehensive 
Cancer Network (10) provide detailed summaries of the literature associated with HER2 
testing and include recommended guidelines for HER2 testing.  This chapter synthesizes 




testing for HER2, and concludes by discussing needed areas for additional research.  As 
such, this literature synthesis will be useful in identifying current issues related to IHC vs. 
FISH testing for HER2, and in deciding upon specific areas in which research is needed 
for future clinical and policy development.   
 
1. 1 Methods and Materials 
 
Literature for this synthesis was identified from searches of the National Library of 
Medicine’s MEDLINE database.  Only studies published in English over the past 10 
years (1999-2008) were considered for inclusion.  Articles with the terms “Receptor, 
erbB-2” and “Breast Neoplasms” and either “Immunohistochemistry” or “In Situ 
Hybridization, Fluorescence” were identified.  Titles of articles were reviewed to identify 
literature relevant to: variability in HER2 testing; comparisons between IHC and FISH; 
costs time, and cost-effectiveness of HER2 testing; and testing algorithms.  References 
cited in identified articles were also reviewed.   
1.2 Results 
1.2.1    Variability in HER2 IHC Results based on Laboratory Characteristics and       
 Scoring 
 
IHC is a relatively simple diagnostic procedure, requiring less time, expertise, and cost 
than many other molecular diagnostic tests (such as FISH).  However, while the ease 
with which IHC can be performed and its widespread use in a majority of laboratories 
performing HER2 testing are two of its advantages (11), IHC test results can exhibit 
substantial variability. Variability in scoring of IHC results can occur between laboratories 
and between personnel in the same laboratory due to several factors. Irrespective of the 
choice of test method, laboratory experience is vital in order to obtain accurate and 




and more standardized IHC testing results as measured by higher levels of IHC and 
FISH concordance. (13) Quality assurance methods in smaller laboratories have been 
reported to be more problematic than those of larger laboratories regarding testing for 
HER2 status. (14)  
 
Poor standardization of immunohistochemical protocols has been blamed for the 
variability in IHC results. Using test results from 12 French laboratories, Vincent-
Salomon et al. evaluated calibration of IHC procedures in those laboratories where poor 
concordance between IHC and FISH results were noted. They demonstrated the 
importance of calibration of immunohistochemical procedures using antibody retrieval 
and antigen dilution in order to improve accuracy and reliability of the process. (7)  
Related to this, Sauer reported that the intensity of IHC staining is dependent on formalin 
fixation, which can vary from laboratory to laboratory, and even within the same 
laboratory. (15) While fixation is an issue with FISH also, the DNA is a more stable target 
for testing. (15) Automated image analysis systems attempt to reduce variability between 
observers by quantifying staining intensity. However, such systems cannot eliminate 
inherent variation until standardization of immunohistochemical processes between and 
within laboratories occurs. (16) 
 
Variability between testing laboratories may be more pronounced for samples that show 
low to intermediate positive results using IHC.  Results from a survey by the American 
College of Pathologists showed excellent agreement between laboratories for cancer 
samples with no HER2 protein overexpression or high levels of overexpression, but 




1.2.2   Variability in IHC Results among Test Antibodies 
 
 
The use of different antibodies (with differing levels of sensitivity and specificity) can 
contribute to the variability of results in IHC. (18-21) Tubbs et al. analyzed 400 infiltrating 
ductal breast carcinoma samples with two antibodies against the HER2 protein: the 
Dako polyclonal antibody (HercepTest) and the monoclonal antibody CB11.  Their 
analysis compared IHC results against the gold standards of gene amplification and 
mRNA profiling. Although the same scoring criteria were used (based on the 
manufacturer’s guidelines for HercepTest), the HercepTest resulted in 23% false positive 
results while the CB11 monoclonal antibody resulted in 17% false positives. (18)  
 
Lebeau et al. evaluated IHC results using five different monoclonal antibodies and two 
polyclonal antibodies. (22)  The monoclonal antibodies tended to identify the same tumor 
samples as HER2 positive while the polyclonal antibodies showed less agreement.  
Further, the monoclonal antibodies identified fewer samples as being HER2 positive 
(26% to 27% of samples) compared to the two polyclonal antibodies (33% and 42%).  
Among 57 samples with no HER2 gene amplification as measured by FISH, positive 
results were seen with IHC using monoclonal antibodies in 1% to 3% of samples.  For 
IHC using the two polyclonal antibodies on these samples, positive results were seen in 
7% and 13% of samples.  Among 20 samples with high levels of gene amplification 
based on FISH, four of the five monoclonal antibodies and both polyclonal antibodies 
indicated positive IHC results for 100% of the samples (one monoclonal antibody 
indicated positive results from only 18 of the 20 samples). (22)  Therefore, the monoclonal 
antibodies had greater specificity compared to the polyclonal antibodies, while both 




1.2.3   FISH vs. IHC  
1.2.3.1   Concordance 
 
As prescription of trastuzumab therapy should rely on the test that is used to determine 
HER2 status, the accuracy and reliability of the HER2 test used can seriously affect 
patient outcomes. The FDA approved HercepTest, InSite and Pathway and their 
corresponding scoring systems (0, 1+, 2+, 3+) are of particular interest due to their 
clinical relevance and widespread utilization with regard to trastuzumab therapy. 
Discordance between IHC and FISH has been reported particularly for intermediate (2+) 
IHC results. Currently, for HercepTest, a score of 3+ is classified as strongly positive and 
a score of 2+ is classified as weakly positive for HER2 overexpression.  For InSite and 
Pathway, both 2+ and 3+ scores are classified as positive. All three tests use similar 
categorization to classify tissues into the 2+ and 3+ scores (Table 1.1). 
 
Several studies have analyzed the validity of IHC testing using FISH as the gold 
standard. A number of these studies have indicated issues with IHC testing, particularly 
with respect to false positive results. (3, 15, 16, 18, 23-26) Wang et al. used a polyclonal 
antibody to perform IHC on 52 infiltrating breast cancer tissues and scored them as “high 
positive”, “medium positive”, “low positive” and “negative.”  Their results showed that 9 
out of 13 specimens evaluated as “medium positive” by IHC failed to show any gene 
amplification using FISH. (3)  Jacobs et al. reanalyzed 48 invasive breast cancer samples 
that had previously been determined to be HER2 negative by two IHC assays as well as 
FISH. (27) Jacobs et al. found that using the HercepTest test, 58.4% of these samples 






Table 1.1: Positive Scores in FDA Approved IHC Assays1 
 
Staining Pattern Score Interpretation 
A weak to moderate complete 
membrane staining is observed in 
more than 10% of the tumor cells 
2+ 1. HercepTest: Weakly 
Positive 
2. InSite: Positive 
3. Pathway: Positive 
(membrane staining ring 
is seen to be thin) 
Strong, complete membrane 
staining is observed in more than 
10% of the tumor cells 
3+ 1. HercepTest: Strongly 
Positive 
2. InSite: Positive 
3. Pathway: Positive 
(membrane staining ring 
is seen to be thick) 
1. Sources: www.dakousa.com, www.ventanamed.com, and www.fda.gov 
 
A majority of the false positive IHC cases (using FISH as a gold standard) are found 
among 2+ results. (18) This suggests that IHC 2+ results cannot reliably be considered 
HER2 positive, as follow up tests using FISH and other IHC protocols on the same 
cancer samples can result in negative HER2 classification. (6, 18, 24, 28-30)  A number of 
studies have reported that a quarter or less of tissue specimens that scored IHC 2+ 
demonstrate corresponding gene amplification by FISH. (6, 22, 28) In a study by Jimenez et 
al., all five 2+ results in an assay performed with the Zymed antibody showed negative 
gene amplification using FISH. (29) 
 
Lebeau et al. reported that of seven antibodies tested (five monoclonal and two  
polyclonal), HercepTest resulted in the greatest number of samples being scored as 
HER2 positive, with a majority of the 2+ results ultimately showing no gene amplification 
by FISH. (22) Tubbs et al. reported that HercepTest showed greater discordance with 
FISH than did the monoclonal antibody CB11 from Ventana. (18) Considering the impact 
of 2+ false positives on patient outcomes and costs, most of these studies recommend 




A number of other studies also report that IHC 0, 1+ and 3+ scores show better levels of 
agreement with FISH results than did 2+ scores. For instance, Kakar et al. reported that 
samples with 3+ IHC staining showed 88% concordance with FISH and 0/1+ staining 
showed 99% concordance with FISH, while 2+ results showed only 35% 
concordance.(21) Thompson et al. reported that only 0 and 3+ results from IHC show 
substantially concordant results with FISH, and that 1+ and 2+ were not clearly 
predictive of gene amplification status. (23) Jimenez et al. found that all cases scored as 
3+ using IHC, with 3 different antibodies (Zymed, clone 31G7; Ventana, clone CB11; 
Dako, polyclonal), showed gene amplification by FISH. (29) Lebeau et al also reported 
that despite the use of different antibodies, IHC 3+ results consistently showed gene 
amplification by FISH. (22) It is important to note that even though discordance between 
0/1+ IHC results and FISH results (i.e., negative IHC and positive FISH results for the 
same sample) has been reported to be as low as less than 1% (19, 21, 31), these 
discrepancies are important due to their impact on the correct (or potentially incorrect) 
HER2 diagnosis, treatment and survival.  
 
Since IHC and FISH do not detect the same biological alterations in cancerous cells (i.e., 
IHC measures overexpression of the HER2 protein while FISH measures gene 
amplification), absolute concordance may never be achieved between these two 
methods. (32, 33) Samples with negative results from IHC testing (scored as 0 or 1+ under 
the HercepTest, Insite and Pathway scoring systems) do not typically show gene 
amplification under FISH analysis. (19, 24, 28, 29, 31, 34) While some studies have reported on 
samples that show gene amplification (i.e., positive FISH results) when IHC results are 
negative (19, 21, 25, 31) ,the proportion of these IHC negative/FISH positive cases is usually 
very small. For example, Ridolfi et al found one IHC negative sample out of 750 invasive 




suggest that samples may be classified as IHC negative/FISH positive (and thus 
potentially IHC false-negative) due to loss of epitope (i.e., an antibody binding site) 
during the fixation process. (19, 31) Another possible explanation for this discordance is 
amplification in the absence of overexpression. (19) Similarly, while most studies report 
good agreement between IHC strongly positive (3+) results and positive FISH results, 
there are 3+ IHC cases that are negative for HER2 amplification based on FISH. (31) 
Dowsett et al found that such FISH negative/IHC positive cases typically have better 
prognosis than FISH positive cases, which suggests that these cases may be IHC false 
positives. (31) In some cases, IHC positive/FISH negative cancers have been attributed to 
protein overexpression in the absence in gene amplification. (21, 35) Also, dual-probe FISH 
(which quantifies the number of HER2 genes relative to the number of chromosomes) 
would classify as negative those cases that overexpress HER2 due to polysomy of 
chromosome 17 rather than multiple copies of the HER gene on a single 
chromosome.(28) While polysomy has an additive effect with gene amplification, 
polysomy without gene amplification can also cause an increase in HER2 protein 
production.  
1.2.3.2   Costs, Time, and Cost-Effectiveness of FISH and IHC 
 
It is clear that FISH costs more and requires more time to complete than IHC. The 
average cost per test has been reported to be approximately $482 for FISH versus $89 
for IHC. (36)   Based on Medicare reimbursements, Elkin et al. valued FISH at $381 while 
HercepTest was valued at $85. (37)  
 
In addition, FISH testing is a longer and more labor-intensive procedure than IHC.  FISH 
requires more time for both sample preparation and analysis compared to IHC. (14) In a 




the Oncor Ventana INFORM FISH kit, CB11 IHC and HercepTest were found to take 1 
day each while FISH required 2 days, with 4 hours on the first day and 7 hours on the 
second. (38) Kakar et al reported that each IHC assay, with a maximum of 40 slides, took 
105 minutes while each FISH test, with a maximum of 20 slides, required 173 minutes 
divided over two days. (21) In addition, laboratory personnel required 3 minutes to analyze 
IHC results but needed over 15 minutes to analyze FISH results. (21)  
 
Few cost effectiveness studies comparing IHC and FISH for HER2 testing have been 
performed. Studies that have compared cost-effectiveness of these two tests are not in 
agreement regarding which test should be used for HER2 testing. (37-38) 
1.2.3.3   Algorithms for HER2 Testing 
 
The extensive discussion in the literature on FISH vs. IHC for HER2 testing informs 
recommendations for how testing should be performed. These recommendations vary 
from advocating the use of IHC as the primary test, using both IHC and FISH, and using 
only FISH. Wolff et al. (9) and Carlson et al. (10) provide algorithms both for initial IHC 
testing and for initial FISH testing, and stress the importance of good laboratory 
practices in order to accurately assess HER2 status.   
 
While FISH is widely considered the more accurate assay, some studies that take into 
account cost, laboratory experience, and expertise required to perform FISH recommend 
IHC as a reliable, accurate and cost effective primary method for HER2 testing. (39) 
Standardized IHC procedures have been recommended in some cases for use as the 
primary method for HER2 detection except when protein expression levels are very 
low.(40) However, this recommendation often comes with the caveat that IHC testing may 




In contrast, Sauer et al. recommended that FISH should be used as the primary testing 
method for HER2 status, even though it is more complex and more expensive than 
IHC.(15) Their analysis of HER2 status in 215 breast carcinomas led them to conclude 
that determining gene amplification is more important than determining overexpression. 
Specifically, Sauer et al pointed out that overexpression without gene amplification 
occurs in cancers that belong to a group with better prognosis than those cancers that 
have gene amplification. (15) Bartlett et al. also recommend the widespread 
implementation of FISH for HER2 testing; they further indicate that IHC could become 
the test of choice in the future if improved test calibration and standardization occur. (41)  
 
Considering the adverse effects of trastuzumab treatment without true positive HER2 
status, retesting of even those cases that show IHC 3+ status with FISH has also been 
recommended. (25) If effective quality control methods and standardization techniques are 
available, the use of IHC as the initial method and FISH to test only equivocal cases may 
be reliable, but concerns exist about this algorithm considering the present state of IHC 
testing. (41) Variations of this algorithm exist, such as the one proposed by Falo et al. that 
suggests the use of IHC with the CB11 antibody as the first step to diagnose positive 
cases. This is followed by reanalyzing all negative cases with HercepTest and then 
utilizing FISH only with those samples that are CB11 negative and HercepTest 
positive.(38) Another variation is suggested by Torrisi et al who recommend using FISH to 
retest all cancers which show complete immunostaining in less than 50% of neoplastic 
cells. (42) 
 
A number of studies, such as that by Arnould et al. (43), have reported that FISH 
amplification status is highly correlated with patient response to trastuzumab therapy.  In 




and a recent letter by Paik et al. (44) indicate equivalent benefits in terms of disease 
progression for women with breast cancer treated with trastuzumab, regardless of 
whether they were HER2 positive or negative (assessed by both IHC and FISH).  
Results of HER2 testing may also be influenced by HER2 expression heterogeneity 
within a tumor; as reported by Striebel et al. (45), repeat testing of tumors with equivocal 
HER2 results changed the HER2 status classification in more than half of 17 biopsy 
specimens.  In developing appropriate testing and treatment recommendation, tumor 
sampling procedures and the potential benefit of trastuzumab among patients with 
equivocal or even negative HER2 results will need further study.   
1.2.3.4   Biological Differences between FISH and IHC 
 
 
FISH and IHC detect different biological components; FISH detects sequences of DNA 
while IHC detects protein overexpression. Apparent discrepancies in test results may 
either be due to artifacts (false positive or false negative test results) or true biological 
differences (overexpression in the absence of amplification or amplification in the 
absence of overexpression).  With respect to biological phenomena, HER2 protein 
overexpression may either be the result of HER2 gene amplification or increased levels 
of HER2 transcription caused by the preferential binding of the HER2 transcription factor 
OB2-1. (46) In some cases, HER2 gene amplification may be present without 
corresponding HER2 protein overexpression when the amplified genes do not actively 
produce their protein products. 
 
FISH positive/IHC negative results and FISH negative/IHC positive results have been 
reported in various studies. (21, 31, 35)   Most of these cases behave in a way that is aligned 




a majority of cases that are positive for HER2 overexpression by IHC but negative for 
gene amplification by FISH have better prognosis than cases that are HER2 positive by 
both tests. (15,31) With regard to FISH positive/IHC negative cases, a majority of them 
behave as true HER2 positive cases; studies have shown these tumors have the same 
survival rates as tumors with positive results on both tests. (15) In addition, clinical 
response to trastuzumab is strongly correlated with gene amplification (as detected by 
FISH). (47) 
1.3   Discussion 
 
We have summarized and synthesized literature on Fluorescence In Situ Hybridization 
and Immunohistochemistry testing protocols for HER2 gene amplification and protein 
overexpression, respectively, in breast cancer. Many published studies show high levels 
of variability with IHC results, while FISH appears to be more reliable and serves as a 
gold standard for testing. IHC protocols vary in terms of the laboratory experience, score 
interpretations, and antibodies used for testing. When IHC results are intermediate, 
literature shows that they cannot be reliably used to determine a cancer’s HER2 status. 
This problem with interpretation of IHC results has been illustrated in several studies, 
particularly with respect to 2+ results, using the FDA approved HercepTest. The 
strengths of IHC are that it is less expensive than FISH and it requires less laboratory 
personnel time and expertise.   
 
While there is a sizeable body of literature comparing different aspects of FISH and IHC, 
we found certain limitations in existing literature. These gaps in research include: 
potential performance characteristics of IHC testing with improved standardization; 
correlations between treatment outcome and test(s) used for HER2 detection; disparities 




vs. FISH testing.  For this first area, a number of studies indicate that calibration and 
standardization of IHC protocols could result in increased accuracy and reliability for this 
test.  Dowsett et al. concluded that standardization and quality control methods are 
imperative to improve both FISH and IHC, particularly in laboratories that are less 
experienced or not centralized. (48) O’Malley et al. indicated that participation in quality 
assurance programs was an effective way to improve the accuracy of IHC test results.(49) 
Despite studies on standardization, the question of whether calibration and 
standardization could result in IHC becoming equal to (or more effective than) FISH in 
terms of accuracy, reliability, and other factors is not clear. It appears that with available 
technology and methods, while IHC shows improved performance when standardized, 
IHC results still may have to be validated by FISH, particularly for ambiguous cases 
(such as with 2+ staining for HercepTest). More studies evaluating whether improved 
IHC methods (in addition to studies quantifying the level of improvement required for 
IHC) could effectively replace FISH are required to fully assess the appropriate roles of 
these two tests for HER2 detection.  
 
In addition, more research is needed with respect to outcomes for breast cancer patients 
based on variations in HER2 testing patterns and treatment. Particularly in light of 
studies reporting benefits from trastuzumab therapy among HER2 negative patients (10, 
44), additional studies are needed to determine the associations among types of HER2 
test(s) used for women with breast cancer, treatment (or not) with trastuzumab therapy, 
and patient outcomes. Given the potential uncertain in identifying appropriate patients for 
trastuzumab therapy, collection of outcomes data associated with test type/results and 
specific treatment received is crucial. Examination of the role of clinical and non-clinical 





Related to evaluation of patient outcomes, studies on cost-effectiveness of HER2 testing 
patterns are much needed.  Several existing studies compare the costs of the tests only 
and do not account for costs associated with outcomes of potentially incorrect treatment.  
For example, cost-effectiveness studies which include the adverse health outcomes as 
well as the loss of time and money involved in treating a patient falsely diagnosed as 
HER2-positive by IHC could result in FISH being classified as being cost-effective (or 
even costs-saving) as compared to IHC.  In the published literature, there is little 
disagreement that FISH is more accurate than IHC.  By performing IHC first, followed by 
FISH for intermediate case, the best possible outcomes would be to classify patients as 
well as would be the case with performing FISH first for everyone.  The argument for 
performing IHC first is therefore largely economic.  Given the potentially serious 
consequences of incorrect trastuzumab therapy (either not treating someone who is 
HER2 positive or treating someone who is HER2 negative), strong evidence is needed 
regarding cost-savings resulting from initial IHC testing or lack of cost-effectiveness for 
initial FISH testing.  Further, such evidence needs to come from “real world” settings 
rather than from studies of IHC vs. FISH that are performed under ideal conditions such 
as select, high quality laboratories.   
 
In this dissertation, we attempt to address some of these areas which have not been 
investigated in detail. Specifically, we examine clinical and non-clinical factors and their 
role in HER2 testing and trastuzumab treatment. In addition, we also determine the cost-
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Impact of Clinical and Non-clinical Factors on the 
Choice of HER2 Test for Breast Cancer 
 
2.1   Introduction 
 
Mortality rates associated with breast cancer have declined in recent years due to earlier 
detection and better treatment methods. (1) Determining cancer stage as well as 
biological characteristics of the tumor such as hormone status and HER2 status is 
critical to providing appropriate treatment. HER2 positive breast cancer is a type of 
breast cancer characterized by amplification of the HER2 gene with subsequent protein 
overexpression. The HER2 gene, the human epidermal growth factor receptor 2, 
encodes a tyrosine kinase and belongs to a family of genes that encode transmembrane 
receptors for growth factors. (2) Gene amplification of HER2 with subsequent protein 
overexpression has been shown to exist in 20 % to 30% of invasive breast cancers. (2-7) 
HER2 amplification (i.e., the presence of an increased number of gene copies per cell) 
and overexpression (i.e., the increased production of protein by a gene) are associated 
with increased tumor aggressiveness and poor prognosis. (2, 3) 
 
Treatment for HER2 breast cancer includes use of a targeted therapy: a humanized 
monoclonal antibody, trastuzumab (Herceptin®) which works against HER2 
overexpressing cells.  This drug has significant benefits for HER2 positive breast cancer 
patients in terms of improving clinical outcomes; however, it is associated with elevated 
risks of cardio-toxicity and with substantial financial costs of over $120,000 for treatment.  
Thus, to ensure appropriate use of this medication for breast cancer treatment, accurate 




There are currently two main types of tests used to assess levels of HER2 in breast 
cancer: Fluorescence in Situ Hybridization (FISH) and Immunohistochemistry (IHC). 
FISH measures HER2 gene amplification while IHC measures levels of the HER2 
protein. The following FISH and IHC tests are FDA-approved for HER2 diagnosis in the 
United States: PathVysion (FISH, Vysis Inc.), INFORM (FISH, Ventana Medical 
Systems), FISH PharmDx (FISH, Dako), InSite (IHC, BioGenex Laboratories, Inc), 
HercepTest (IHC, Dako), and Pathway (IHC, Ventana).  
 
A number of published reviews that have evaluated HER2 testing methods show high 
levels of variability within IHC results, while FISH is more reliable and generally serves 
as a gold standard for testing. (6-20) IHC protocols vary in terms of laboratory experience, 
score interpretations, and the kinds of antibodies used for testing. (7-16) IHC results for 
HER2 testing are scored form 0 (negative result) to 3+ (positive). When IHC HER2 test 
results are intermediate (2+), literature shows that they cannot be reliably used to 
determine a cancer’s HER2 status. (6, 12, 17-20) The strengths of IHC are that it is less 
expensive than FISH and it requires less laboratory personnel time and expertise. (8, 16, 22-
23) 
 
FISH testing for HER2, which is more expensive and requires greater laboratory 
expertise and more time than does IHC, is regarded as more accurate as it is associated 
with better response rates to anti-HER2 therapy (24-27).  That is, HER2 status determined 
by FISH correlates better with response to anti-HER2 therapy than does HER2 status 
determined by IHC.  Despite the superiority of FISH in terms of accuracy and 
reproducibility, both IHC and FISH continue to be used for HER2 testing. It is therefore 
important to assess the factors that influence which of these tests is selected for use. 




factors that are associated with disparities in breast cancer diagnosis, treatment and 
survival. (28 – 34)  Socioeconomic status is associated with breast cancer stage at 
diagnosis, treatment type, and likelihood of mortality (31); for example, advanced stage 
tumors are found in greater proportions in minorities when compared to white women (32) 
and uninsured patients and those covered by Medicaid are more likely to have advanced 
stage breast cancer at the time of diagnosis when compared with patients who are 
privately insured. (34)  While these studies have considered the impact of various 
sociodemographic factors on diagnosis and treatment of breast cancer, the role of such 
factors on the choice of HER2 test has not been examined. The goal of this study is to 
determine whether certain clinical and non-clinical factors affect the choice of HER2 test 
among women who are tested for HER2.  
 
2.2   Materials and Methods 
 
The data utilized for this research was provided by The American Cancer Society, which 
purchased the data set from Rabbit Healthcare Systems. Rabbit Healthcare Systems is 
located in Austin, TX, and primarily develops electronic medical records for oncology 
practices.  The data set used for this study consists of information from the Rabbit 
Healthcare Systems electronic medical records from six private practice oncology 
practices.  The data-set is unique in that it includes information on HER2 status that is 
not currently available from other large cancer data-sets, such as SEER (Surveillance 
Epidemiology and End Results, from the National Cancer Institute) and the National 
Cancer Database. (35-36) The Rabbit Health Systems data-set includes the type of HER2 
test performed (IHC, FISH, or neither) and the results of the HER2 test, which is 




medical claims data-sets include patients with one type of insurance (e.g. Medicare or 
private insurance), the Rabbit data-set includes patients with several types of insurance. 
 
The entire data set contains information on 3348 breast cancer patients diagnosed from 
1972 to 2008. Table 2.1 summarizes the information available in the data-set. Table 2.2 




























Demographics 1. Unique Patient ID 
2. Date of birth 
3. Zip code (first 3 numbers) 
4. Diagnosis date 
5. ICD9 Code 
6. Diagnosis description 
7. Primary insurance 
8. Secondary insurance 
9. Date of death (if applicable) 
Diagnosis  1. Unique Patient ID 
2. ICD9 Code 
3. Date of diagnosis 
4. Description of diagnosis 
5. Level of diagnosis (primary, secondary) 
Tumor Markers 1. Unique Patient ID 
2. Date of test 
3. Name of marker (ER, PR, HER2) 
4. Status (Positive/Negative) 
5. Test  
Staging 1. Unique patient ID 
2. ICD9 Code 
3. Date of staging 
4. Tumor Size (T) 
5. Node (N) 
6. Metastasis (M) 
7. Tumor Grade 
Targeted Therapy & Chemotherapy 1. Unique patient ID 
2. Date of treatment 
3. Drug name 
4. Generic drug name 
5. Dose 
6. Units of dosage 
Hormone Therapy 1. Unique patient ID 
2. Medication name 
3. Dose 
4. Date of treatment 
Vitals 1. Unique patient ID 
2. Date of visit 
3. Weight 
4. Height 
5. BP systolic 
6. BP diastolic 
7. Pulse  
8. Respiratory rate 
9. Temperature 
Office Visit Information 1. Unique patient ID 
2. Date of visit 
3. Visit type (New patient, follow up) 







Table 2.2: Details of Clinical Practices that Contributed to Data-set 
 
Practice Code Region Number of 
Physicians 
A Los Angeles 
 
2 
B  West Texas 
 
3 
C Washington State 
 
6 
D South Dakota 
 
1 
E Central Texas 
 
3 




This study investigated whether certain factors are associated with the choice of test 
used for HER2 testing. Therefore, the study population included patients whose data 
had information on the type of HER2 test performed (IHC or FISH). Patients were 
excluded from analysis if the HER2 test field did not have any information or was 
indeterminate. Patients were also excluded from the analysis if values for any of the 
independent variables were missing or indeterminate. Based on this exclusion method, 
1338 patients met the criteria for this study. Analyses were performed using multivariate 
logistic regression to model the impact of location, stage, date of diagnosis, insurance 
coverage, hormone status and age on the choice of HER2 test type. Multivariate logistic 
regression was selected due to its ability to serve as an effective technique in the 
analysis of the effect of covariates on a dichotomous dependent. (23) The dependent 
variable was dichotomous, coded as FISH HER test (=1) versus IHC HER2 test (=0).  All 
analyses were performed using SPSS statistical software version 16.0 for Windows, 




2.3   Analysis 
2.3.1   Preliminary Models 
In preliminary models, the following independent variables were included: 
- Location: coded as five nominal dichotomous variables, one 
variable each for Washington, Los Angeles, South Texas, 
Central Texas, and West Texas with the South Dakota location 
serving as the reference. South Dakota is selected as the 
reference since it is well defined (i.e., not defined as “other” or a 
miscellaneous category; a criterion which is satisfied by all 
location variables) and does not have the lowest number of 
cases (Los Angeles has the lowest number of patients with 50). 
Leaving out Los Angeles (the smallest location) and the West 
Texas (the largest location with 457 patients) to avoid 
comparisons with either extreme, any of the remaining three 
locations could have been used as the reference.  
- Diagnosis Date: coded as a dichotomous variable which takes 
one of two values depending on whether a patient was 
diagnosed before or after publication of HER2 testing guidelines 
in 2001. Patients diagnosed in 2001 fell into the category of 
those diagnosed after publication of guidelines since these 
guidelines were published in early 2001 and were officially 
considered the 2000 update to previous guidelines. 
- Age (continuous variable) 
- Complete TNM staging (T variables – Tumor Size, N variables – 
lymph node invasion level, M variables– presence of distant 




example T is coded with 3 separate dichotomous variables T0, 
T1, T2 with T3/T4 serving as a reference) 
- Insurance (Medicare, Medicaid, Medicare with supplemental 
Private insurance, Private or Uninsured). Insurance was divided 
into 4 separate nominal (dichotomous) variables with uninsured 
status being the reference group: Medicaid, Medicare (with or 
without secondary Medicaid), Medicare with supplemental 
private insurance, and Private Insurance. 
- Estrogen Receptor (ER) status (nominal dichotomous variable), 
and Progesterone Receptor (PR) status (nominal dichotomous 
variable).  
 
Age, insurance, N and M staging, and hormone status (which includes both ER and PR 
variables) were eventually removed from the model when no statistically significant 
association with the dependent variable was observed. 
 
2.3.2   Final Model 
A total of 1338 patients were included for the study (table 2.3). The final model consists 
of nine independent variables: five location variables, three T stage variables, and a 
variable which indicates whether initial breast cancer diagnosis was before or after 
publication of testing guidelines in 2001. Almost one-third (31.84%, or 426 out of 1338) 
of breast cancer patients in the data set were tested with FISH, over two thirds were 
tested with IHC (68.16%, or 912 out of 1338), and 26.31 % of patients (352 out of 1338) 
were HER2 positive. The independent variables in the final model (table 2.4) are Loc 




T0, T1, T2 and DiagnosisDate. With respect to the dependent variable, all interpretations 
are with respect to the higher category (HER2 Test = 1 = FISH). 
 













A (Los Angeles)  
50 (3.74%) 
 






D (South Dakota) 
137 (10.24%) 
 
E (Central Texas) 
381 (38.48%) 
 
F (South Texas) 
































Table 2.4: Variables in Final Model – Factors that Affect Choice of HER2 Test 
 
Variable Name Description Type Possible Values 
HER2 Test FISH or IHC (HER2 
testing method) 
 




0 – IHC 
1 – FISH 
 
LocALosAngeles Location of oncology 
practice 
 
Independent  Nominal 
Dichotomous 
(Reference: Loc D –
S. Dakota) 
 
0 – Not Location A 
1 – Location A 
 





(Reference: Loc D – 
Midwest, S. Dakota) 
 
0 – Not Location B 
1 – Location B 
 
LocCWashington Location of oncology 
practice 
Independent  Nominal 
Dichotomous 
(Reference: Loc D –
S. Dakota) 
 
0 – Not Location C 
1 – Location C 
 
LocECentralTexas Location of oncology 
practice 
Independent  Nominal 
Dichotomous 
(Reference: Loc D –
S. Dakota) 
 
0 – Not Location E 
1 – Location E 
 
LocFSouthTexas Location of oncology 
practice 
Independent  Nominal 
Dichotomous 
(Reference: Loc D –
S. Dakota) 
 
0 – Not Location F 
1 – Location F 
 
T0 Indicator of whether 
tumor is in T0/Tis 




Independent  Ordinal  
 
0 – Not Tis/T0 
1 – Tis/T0 
 
T1 Indicator of whether 





Independent  Ordinal 0 – Not T1 
1 – T1 
 
T2 Indicator of whether 





Independent  Ordinal  
 
0 – Not T2 
1 – T2 
 
DiagnosisDate Indicator of whether 
disease diagnosis 
was before or after 
2001   
Independent  Nominal 
Categorical 
 
0 – Before 2001 





2.4   Results 
 
The results of the final model demonstrate that diagnosis date (before or after 2001), 
location and T value have a statistically-significant effect on the choice of HER2 test (see 
table 2.5 for output for logistic regression). The model is well-fitted with a Hosmer-
Lemeshow Goodness of Fit statistic of 0.462 (table 2.6). This indicates that the null 
hypothesis (which states that there is no difference between observed values of the 
dependent variable and those values of the dependent variable that are predicted by the 
model) should not be rejected. In other words, the Goodness of Fit statistic indicates that 
the model's estimates fit the data at an acceptable level. (37) The Wald statistic for each 
of the significant effects (Location A – Los Angeles, Loc E – Central Texas, Loc F – 
South Texas, Stage T0, Diagnosis date) is large, showing that these variables are 
statistically significant predictors of the dependent variable (table 2.5).  
 
Table 2.5: Logistic Regression Output 



















Odds Ratio Lower Upper 
Loc A: Los Angeles  1.101 .396 7.721 1 .005 3.007 1.383 6.538 
Loc B: West Texas -.137 .298 .211 1 .646 .872 .486 1.564 
Loc C: Washington .476 .361 1.735 1 .188 1.609 .793 3.267 
LocE: CentralTexas 3.023 .287 110.611 1 <.001 20.543 11.696 36.082 
LocF: SouthTexas .854 .298 8.219 1 .004 2.350 1.310 4.213 
Stage T0 -1.373 .660 4.331 1 .037 .253 .070 .923 
Stage T1 -.057 .255 .050 1 .823 .945 .573 1.557 
Stage T2 .094 .269 .124 1 .725 1.099 .649 1.860 
Diagnosed Before 
2001 
-1.154 .242 22.676 1 <.001 .315 .196 .507 




Table 2.6: Goodness of Fit of the Model 
 
Hosmer and Lemeshow Test 
 Chi-square df Sig. 
 7.708 8 .462 
 
 
Patients in Loc E (Central Texas), Loc F (South Texas), and Loc A (Los Angeles) are 
significantly more likely to be tested with FISH than those in the reference location (D).  
The odds that a person in Central Texas (Location E) is tested with FISH are 20.543 
times the odds that a person at the South Dakota site  (Location D) is tested with FISH. 
The odds that a person in South Texas (Location F) is tested with FISH are 2.35 times 
the odds that a person in South Dakota (Location D) is tested with FISH. The odds that a 
person in Loc A (Los Angeles) is tested with FISH are also greater than the odds that a 
person in South Dakota is tested with FISH, by a factor of 3.007.  
 
Patients who have Tis/T0 breast cancer are significantly less likely to be tested with 
FISH than those who are in the T3/T4 stages. The odds of a person in stage Tis/T0 
breast cancer being tested with FISH are 0.253 times the odds of that of a person who is 
in stage T3/T4 being tested with FISH. The likelihood of being tested with FISH for 
patients with T1 and T2 disease are not significantly different from the likelihood among 
T3/T4 patients. 
 
Patients diagnosed prior to the publication of HER2 guidelines in 2001 are less likely to 
be tested with FISH than those diagnosed after 2001. The odds of a person diagnosed 
before 2001 being tested with FISH is 0.315 times the odds that a person diagnosed 





These results indicate that location, diagnosis date, and T stage have an effect in the 
choice of HER2 test. Specifically, for patients considered in this study, those tested in 
Central Texas, South Texas, and Los Angeles were more likely to be tested with FISH 
than those in the Midwest. Also, with regard to diagnosis date, patients diagnosed after 
2001 are more likely to be tested with FISH than those who were diagnosed before 
2001.  Patients tested for HER2 during the Tis/T0 stage of breast cancer are less likely 
to be tested with FISH than those in T3/T4 stage. 
2.5   Discussion 
 
Based on the statistical analysis performed, it is seen that location, diagnosis date and 
stage have significant effects on the choice of HER2 test. With diagnosis date, it is seen 
that those tested after 2001 were more likely to be tested with FISH than those tested 
prior to 2001, a result that that can be explained by the publication of major HER2 
testing guidelines in 2001. The case with location and stage is more complex. Each 
effect is now considered in detail.  
2.5.1   Location 
 
With respect to location, patients tested in Central Texas, South Texas, and Los Angeles 
were more likely to be tested with FISH than those in Location D (South Dakota). 
Previous studies have explored the relationships between physician specialty, 
race/ethnicity, insurance and quality of care for women with breast cancer. (38-42) These 
studies suggest that African American women may not receive the same standard of 
care as do White women (40), although breast cancers in African American women tend 
to be more aggressive than those in White women. (41) No published studies identified to 




patients with breast cancer, and information on race/ethnicity was not available in the 
data set for the current study.  While it is likely that the proportions of African American 
women among the breast cancer patient populations in the Los Angeles and two Texas 
sites were greater than the proportion in the South Dakota site, it is difficult to speculate 
whether this contributed to the observed differences in type of HER2 test used.  Further 
investigation of the racial and ethnic makeup of the various locations considered in this 
study could lead to more insights in this respect.  
 
In a 2004 retrospective study of variables affecting HER2 testing, Stark et al. found that 
surgical oncologists were more likely to test for HER2. (38) This correlates with greater 
survival of breast cancer patients when treated by surgical oncologists. (42)  While the 
data set used in this research contained information on the number of physicians in each 
practice, the specialty practice area of each physician was not provided. The specialty 
area and associated training of the physicians in the clinics considered could have 
influenced the choice of HER2 test and is worth examining in future studies.  
2.5.2   Diagnosis Date 
HER2 testing patterns during and after 2001 are significantly different than prior to 2001; 
this effect can be explained by the publication of major HER2 testing guidelines in 
2001.(43) The relevant segment from the 1997 guideline and the 2001 update is 
reproduced below: 
 
“1997 Recommendation: Present data are insufficient to recommend the use of c-erbB-2 
(HER-2/neu) gene amplification or overexpression for management of patients with 




2000 Recommendation: c-erbB-2 overexpression should be evaluated on every primary 
breast cancer either at the time of diagnosis or at the time of recurrence. Measures of c-
erbB-2 amplification may also be of value.” (43) 
This recommendation unequivocally confirms that all primary breast cancer patients 
must be tested for HER2. Around the time of this publication in early 2001, several 
studies appeared regarding the superiority of FISH in terms of accuracy and correlation 
with clinical outcomes. (6, 11-12, 15, 19-20, 24)  When the recommendation of the 2001 
guidelines is considered along with the observation of various major publications 
regarding FISH being the better test, it appears likely that a shift towards using FISH 
began to occur – an effect we see in the present analysis.  
2.5.3   Stage 
TNM staging (Tumor size, Node and Metastasis) information was provided in the data 
set used for this research. In preliminary models it was seen that N and M values were 
not significantly associated with the choice of HER2 test; these factors were 
subsequently removed from the model. The T stage, however, has a significant 
association, with patients with lower T stage (i.e., small tumors) being less likely to 
receive FISH testing. Tis/T0 tumors maybe Lobular Carcinoma In Situ (LCIS, also known 
as Lobular Neoplasia; technically a non-cancerous and non-invasive condition which 
increases the risk of developing cancer in the future), Ductal Carcinoma In Situ (DCIS) 
or Stage IIA invasive breast cancer, depending on certain factors, including T, N and M 
values of the tumor (44). For LCIS and DCIS tumors, the T, N and M values are Tis, N0 
and M0 respectively, while for stage IIA these values are T0, N1 and M0. In the present 
study, all Tis/T0 tumors included in the analysis except for one (which was stage IIA 




assessment of HER2 status among LCIS or DCIS patients. Furthermore, the value of 
HER2 testing in DCIS cases remains uncertain, with some studies finding a link between 
disease progression and/or recurrence and HER2 status in DCIS, while other studies 
showing no such associations (45 - 48). For example, one particular study reported an 
association between HER2 gene amplification in DCIS tumors and the expression of 
specific genes linked with suppression of apoptosis, another study implicated HER2 
signaling in early breast tumorigenesis, while a third study found that HER2 does not 
play a major role in transformation of DCIS to invasive ductal carcinoma (46-48) Further 
examination regarding differences in outcomes for women with DCIS who are tested and 
treated (if appropriate) for HER2 positive breast cancer is required but at this time, the 
value of HER2 testing (with FISH or IHC) for DCIS remains largely unknown. The same 
is true for LCIS. At this time, with the value of HER2 testing for these In Situ tumors not 
having been clearly established, the results of this study show that physicians choose to 
test DCIS and LCIS cases with the older, quicker and less expensive test (IHC).  
 
2.6   Conclusion 
 
Analysis of factors associated with choice of HER2 test shows that location, diagnosis 
date (before or after 2001) and T-stage have significant effects on whether FISH or IHC 
is selected. Patients receiving treatment at the Central Texas, South Texas, and Los 
Angeles study sites are more likely to be tested with FISH than patients treated at the 
South Dakota site. Patients tested after the 2001 publication of updated guidelines were 
more likely to be tested with FISH – an effect explained by the emphasis of the 
guidelines that all breast cancer patients must be tested for HER2 and the publication 
since of numerous studies advocating the use of FISH over IHC. Finally, patients with 




to due the lack of evidence available regarding the value of HER2 testing in In Situ 
tumors. Further studies on the relationships between race/ethnicity of patients, physician 
specialties and HER2 testing sites, In Situ tumors and the benefit (if any) of HER2 
testing and suitable follow-up treatment, are needed to provide more clarity regarding 
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Factors that Affect Treatment with Trastuzumab in 
Breast Cancer Patients 
 
3.1   Introduction 
 
HER2 breast cancer is an aggressive form of the disease associated with increased 
tumor aggressiveness and poor prognosis. (1-2) Gene amplification of HER2 with 
subsequent protein overexpression has been shown to exist in 20 % to 30% of invasive 
breast cancers. (1-6) While HER2 breast cancers are prevalent in one fourth of the breast 
cancer population, the availability of targeted therapy for these cancers has provided 
significant benefit in terms of health outcomes. Trastuzumab (Herceptin®) is a 
humanized monoclonal antibody specifically indicated for treatment of HER2 positive 
breast cancer. HER2 status is the only factor currently specified by the FDA as being 
relevant in the decision regarding whether trastuzumab is prescribed or not. This study 
determines whether other factors, clinical and non-clinical, influence the prescription of 
this drug.  
 
The American Cancer Society estimated that in 2008 over 180,000 women would be 
diagnosed with breast cancer, but also found that the rates of death from breast cancer 
have declined due to earlier detection and better treatment. (7)  In addition to determining 
tumor stage and grade, optimal treatment involves determination of tumor characteristics 
such as estrogen and progesterone receptor status as well as HER2 status. 
Trastuzumab may be prescribed as adjuvant treatment for node-negative or node-




prescribed as primary single agent treatment or in combination with taxol (for patients 
who have previously received chemotherapy regimens) for metastatic breast cancer. (8)  
 
Trastuzumab works synergistically with chemotherapy in HER2 overexpressing cancer 
cells by selectively binding to the extra-cellular domain of the HER2. (7, 9) Through this 
binding, trastuzumab stops the HER2+ cancer cell from continuing its proliferation. (10) In 
addition, the human immune response recognizes and destroys trastuzumab coated 
cells. (10) While trastuzumab has significant benefits for HER2 positive breast cancer 
patients it is associated with elevated risks of serious adverse events and with 
substantial monetary costs.  Trastuzumab increases the risk of developing ventricular 
dysfunction and congestive heart failure. (11-12) Thus, to ensure appropriate use of this 
medication for breast cancer treatment, testing for HER2 is of critical importance. There 
are currently two main types of tests used to assess levels of HER2 in breast cancer: 
Fluorescence in Situ Hybridization (FISH) and Immunohistochemistry (IHC).  
 
A study by UnitedHealth Group, a large private insurance organization, found that 12% 
of patients treated with anti-HER2 therapy were not positive for HER2 or were not tested 
for HER2 at any point. (13) This led to UnitedHealth Group requiring that HER2 status be 
reported in trastuzumab claims. Such a discovery opened the door to an important 
question: Do other factors, including non-clinical issues such as insurance status and/or 
clinical markers, play a role with regard to prescription of trastuzumab? How do these 
factors play a role, and what is their relative importance? Understanding the relationship 
between these factors and the prescription of trastuzumab therapy will serve as a 
foundation in improving quality of care given to breast cancer patients, by ensuring that 





3.2   Materials and Methods 
 
The data utilized for this research was provided by The American Cancer Society. The 
data was collected by Rabbit Healthcare Systems (Austin, TX).  The data includes 
information on patients diagnosed from 1972 to 2008 in 6 outpatient oncology practices 
in the United States. The entire data set contains information on 3348 invasive breast 
cancer patients collected from each visit made by patients to the physician’s office 
during this time. The subset of data used for this particular study consists of 4 files, each 
containing categorical data. A detailed view of the content of the relevant files utilized for 
this study is provided in Table 3.1. In addition, Table 3.2 gives details about the six 
outpatient oncology practices that contributed to this data-set.  
 
The study population included those patients who received some form of chemotherapy 
(such as taxol or carboplatin) and/or targeted therapy (trastuzumab). Patients were 
excluded from the analysis if the values for any of the independent variables were 
missing or indeterminate. Patients who were diagnosed before the first FDA approval of 
trastuzumab in September 1998 were also excluded from the analysis since the drug 
was not available outside the clinical trial setting before this time. Based on these 
criteria, 683 cases were included for the study. Multivariate logistic regression was used 
to model the impact of location, stage, diagnosis date, insurance coverage, hormone 
status, HER2 status, triple negative status, HER2 test and age on whether anti-HER2 
therapy (trastuzumab) is given or not . Logistic regression is selected since it serves as 
an efficient technique when dealing with a dichotomous dependent variable. (14) SPSS 






Table 3.1: Details of Data Files 
 
File Number Description Fields 
1 Demographics 10. Unique Patient ID 
11. Date of birth 
12. Zip code (first 3 numbers) 
13. Diagnosis date 
14. ICD9 Code 
15. Diagnosis description 
16. Primary insurance 
17. Secondary insurance 
18. Date of death (if applicable) 
2 Tumor Markers 6. Unique Patient ID 
7. Date of test 
8. Name of marker (ER, PR, 
HER2) 
9. Status (Positive/Negative) 
10. Test  
3 Staging 10. Unique patient ID 
11. ICD9 Code 
12. Date of staging 
13. Tumor Size (T) 
14. Node (N) 
15. Metastasis (M) 
16. Tumor Grade 
4 Targeted Therapy & Chemotherapy 7. Unique patient ID 
8. Date of treatment 
9. Drug name 
10. Generic drug name 
11. Dose 
12. Units of dosage 
 
 
Table 3.2: Details of Clinical Practices that Contributed to Data-set 
 
Practice Code Region Number of 
Doctors 
A Los Angeles 
 
2 
B  West Texas 
 
3 
C Washington State 
 
6 
D South Dakota 
 
1 
E Central Texas 
 
3 








3.2.1   Preliminary Models 
 
The dichotomous dependent variable in this study is Trastuzumab, which takes on a 
value of 1 if trastuzumab is given and 0 if trastuzumab is not given. In preliminary 
models, the following independent variables were included for the analysis: 
- HER2 Test: FISH or IHC, coded as a nominal dichotomous variable. 
- Hormone Status: two variables - Estrogen Receptor (ER) status (nominal 
dichotomous variable), and Progesterone Receptor (PR) status (nominal 
dichotomous variable). 
- Triple Negative Status: indicates if a patient is ER-, PR- and HER2-, coded as a 
nominal dichotomous variable. 
- TNM Stage Variables: specifies complete TNM staging : T – Tumor Size, N 
variables – lymph node invasion level, M variables– presence of distant 
metastasis, each coded as a set of ordinal dichotomies; for example T is coded 
with 3 separate dichotomous variables T0, T1, T2 with T3/T4 serving as a 
reference. 
- DiagnosisDate: dichotomous variable which indicates whether patients were 
diagnosed before or after publication of major HER2 testing guidelines in 
2001.(15) 
- Age (continuous variable) 
- Location: coded as five nominal dichotomous variables, one variable each for 
Washington State, Los Angeles, South Texas, Central Texas, and West Texas 
with the South Dakota site serving as the reference. Any of the location variables 
would have served as a suitable reference since all are well defined (i.e. not 
defined as “other”) and comparisons with any of them would be meaningful (as 




selected since geographically, it is the most different from the remainder of the 
categories (the others all being on the West coast or in Texas) which serves as a 
concrete reference.  
- Insurance: divided into the following 4 separate nominal dichotomous variables 
with Private insurance status serving as the reference: Medicaid, Medicare (with 
or without secondary Medicare), Medicare with supplemental private insurance, 
and Uninsured. Private insurance status is chosen as the reference since it is 
well defined and is not the smallest insurance category.  
- HER2 Status: A nominal variable which takes on one of three values depending 
on whether the HER2 status of the patient is unknown, negative or positive. 
Unknown HER2 status indicates that HER2 status information was not obtained 
for the patient, i.e., the patient was not tested for HER2. 
 
HER2 test, ER status, PR status, Triple Negative Status, TNM staging variables, 
DiagnosisDate and Age were removed from the model when no statistically significant 
associations with the dependent variable was observed. 
 
3.2.2   Final Model 











- Medicaid  
- Medicare (Alone or with secondary Medicaid) 
- MedicarewithPriv 
- HER2 Status 
 
As in preliminary models, with respect to location, Location D (South Dakota) is treated 
as the reference and with respect to insurance, Private insurance is treated as the 
reference.  
 
From the 683 included patients, 23.69% were given trastuzumab while 27.38% were 
determined as HER2 positive (by either FISH or IHC). 19.18% of the 683 patients were 
HER2 positive and received trastuzumab, while 2.05% of patients were HER2 negative 
and treated with trastuzumab. Of the 683, 1.46% had unknown HER2 status and were 





























































































3.3   Results 
 
The final model shows that location and HER2 status have significant effects on whether 
trastuzumab therapy is given or not (see table 3.4). In addition to these two factors, we 
see a non-significant trend of patients with Medicare and supplemental private insurance 
not receiving trastuzumab.  
 
The Hosmer-Lemeshow Goodness of Fit test (see table 3.5) for the model has a p-value 
of 0.291. Since this value is greater than 0.05, it indicates that the null hypothesis (which 
states that there is no difference between observed values and those values that are 















Hosmer and Lemeshow Test 
Step Chi-square df Sig. 




























Ratio Lower Upper 
LocALosAngeles -.200 .544 .136 1 .713 .818 .282 2.377 
LocBWestTexas -.742 .484 2.349 1 .125 .476 .184 1.230 
LocCWashington -.444 .526 .715 1 .398 .641 .229 1.796 
LocECentralTexas -.674 .511 1.739 1 .187 .510 .187 1.388 
LocationFSouthTexas -1.354 .550 6.062 1 .014 .258 .088 .759 
NoInsurance -20.545 9427.791 .000 1 .998 .000 .000 . 
Medicaid -.462 .465 .984 1 .321 .630 .253 1.569 
Medicare -.849 .599 2.006 1 .157 .428 .132 1.385 
MedicarewithPriv -.693 .368 3.543 1 .060 .500 .243 1.029 
HER2Status   190.562 2 .000    
HER2Status Unknown -2.937 .393 55.853 1 .000 .053 .025 .115 
HER2Status Negative -4.228 .325 168.952 1 .000 .015 .008 .028 




In addition, the Wald statistic for each of the significant covariates is large, confirming 
that these variables indeed have significant effects on the dependent variable (see table 
3.4). 
 
Examination of the odds ratio in Table 3.4 shows that patients treated in Location F 
(South Texas) are less likely to be given trastuzumab than those treated in Location D 
(South Dakota). Specifically, the odds that a person at the South Texas site (Location F) 
is given trastuzumab are 0.258 times the odds that a person at the South Dakota site 
(Location D; reference) is given trastuzumab. With respect to HER2 status, patients who 
have unknown or negative HER2 status are less likely to be given trastuzumab than 
those who are HER2 positive. The odds that a HER2 unknown patient is given 
trastuzumab are 0.053 times the odds that a HER2 positive patient is given trastuzumab. 
Similarly, the odds that a HER2 negative patient is given trastuzumab are 0.015 times 
the odds that a HER2 positive patient is given trastuzumab. Alternatively, this may be 
stated as follows: Being HER2 positive significantly increases a patient’s odds of 
receiving trastuzumab. From the output of the logistic regression, it is also seen that 
there is a trend of patients with Medicare and supplemental private insurance not 
receiving trastuzumab, but since the p value is greater than 0.05, this represents a non-
significant trend. The cause for this trend being non-significant may be due to limited 
statistical power. 
 
3.4   Discussion 
 
Treatment for HER2 breast cancer should follow confirmation of positive HER2 status 
using Florescence In Situ Hybridization or Immunohistochemistry. Official guidelines 




be used in patients who have demonstrated HER2 overexpression. (8, 16) Determination 
of HER2 status prior to prescription of trastuzumab is critically important not only due to 
the benefit of this therapy for HER2 positive tumors, but also due to the potential for 
serious side effects of this therapy for all those who receive it. The risk of side effects of 
trastuzumab, which include cardiac dysfunction, pulmonary toxicity (such as pleural 
effusions and pulmonary edema), infection, infusion reactions (which may be mild or life-
threatening depending on the patient), neutropenia, and anemia remain for all patients 
who receive trastuzumab, irrespective of their HER2 status. (8) A retrospective analysis 
that assessed cardiac dysfunction rates due to trastuzumab treatment from records of 
patients enrolled in any one of seven phase II and phase III trials for trastuzumab 
conclusively determined that the drug is associated with an increased risk of cardio-
toxicity. (11) The risk for cardiac dysfunction, as assessed from these seven clinical trials, 
was as follows: 27% of patients receiving trastuzumab with anthracycline and 
cyclophosphamide, 13% of patients receiving taxol and trastuzumab and 3% to 7% of 
patients receiving trastuzumab as a single agent experienced cardiac dysfunction. (11) In 
comparison, 1% of patients receiving taxol as a single agent experienced cardiac 
dysfunction. (11) The severity and frequency of serious side effects underscores the 
importance of adhering to prescription guidelines for trastuzumab.  
 
HER2 positive status is currently the only requirement for receipt of trastuzumab 
therapy. The results of this study show that patients who are HER2 positive are 
significantly more likely to receive trastuzumab than those who are HER2 negative or 
whose HER2 status is unknown. Although this analysis shows that trastuzumab is widely 
prescribed only for HER2 positive tumors, further analysis is needed to determine why it 
is prescribed (even in small numbers) to those who are HER2 negative (or whose HER2 




HER2 positive (table 3.6). Follow up is required with non-HER2 positive patients who 
have been given trastuzumab particularly in light of studies reporting benefit from 
trastuzumab therapy among HER2 negative patients. (17-18) If the clinical benefit of 
trastuzumab is established for HER2 negative tumors, re-assessment of trastuzumab 

























Table 3.6: Trastuzumab and HER2 Information by Location  
Note: All percentages are expressed in terms of percent of total number of patients in that location. 
Location Total Number HER2+ Total  
Given 
Trastuzumab 
per location  
 
HER2 +  



































































































From the present analysis, it is seen that patients treated in South Texas (Location F) 
are less likely to receive trastuzumab than those treated at the South Dakota site 
(Location D; reference location).  The current data set does not have race/ethnicity or 
socioeconomic information, which may be some of the underlying reasons behind the 
location effect. It is likely that the Texas and Los Angeles location have greater Black 
and Non-Hispanic White population but it is difficult to speculate further about what this 
result means. However, it does lead us to conclude that there is the possible existence 
of disparities based on location. Further studies are required to conclusively determine 
the cause of these differences. From the available data, it is clear that fewer patients 
presented with HER2 positive status in Location F than in any of the other sites, a factor 
that influences trastuzumab prescription (table 3.6). However, not all HER2 positive 
patients in Location F (or in any of the locations) were given trastuzumab. This could be 
due to one or more of the following: medical reasons (such as infusion reactions at the 
time of initial administration of the drug or pre-treatment cardiac illness which would 
preclude patients from receipt of trastuzumab therapy) or patient refusal. Patient refusal 
to begin or continue trastuzumab therapy has been documented (18, 19) and could be due 
to financial reasons. While private insurance plans will cover trastuzumab for HER2 
positive breast cancer patients in node negative and node positive cancers or in 
metastatic breast cancer (20), the high cost of trastuzumab (over $3000 per month) may 
push the yearly coverage maximum for some patients above their insurance plans. The 
cost of trastuzumab treatment is a serious of an issue for all patients.  However, some 
relief is provided by Genentech, which pays costs towards trastuzumab for uninsured 
and underinsured patients in the United States in certain cases (after ineligibility for all 
forms of public insurance are confirmed by the company) through the Genentech Access 
to Care Foundation. (21-22) If Genentech will pay for trastuzumab treatment in the United 




uninsured patients being less likely to receive the drug. It has been shown that patients 
covered by Medicare do not routinely undergo HER2 testing that and clinical judgment 
may replace histological findings when it comes to trastuzumab use among Medicare 
patients and this scenario may be extendable to uninsured patients. (23) In addition, 
Medicare covers costs of trastuzumab only for metastatic breast cancers and not for 
adjuvant treatment of node-negative or node-positive non-metastatic breast cancer.  (23-
24)   This could be the reason we see a non-significant trend for some Medicare patients 
(those with supplemental private insurance). It is likely that a similar effect is not seen for 
other non-private insurance groups due to lack of power.  
 
To further understand why all HER2 positive patients are not given trastuzumab and why 
geographic location has a significant effect on the prescription of this drug, more 
extensive analysis of insurance coverage and detailed analysis of patient 
adherence/refusal patterns with regard to treatment are required. In addition, analysis of 
race, ethnicity and socioeconomic status of patients could provide insight into whether 
these factors play a causal role with regard to the effect of location and insurance on 
trastuzumab prescription. Currently, oncology clinics and hospitals need to evaluate their 
prescription patterns of anti-HER2 therapy to ensure that they are adhering to 
guidelines. In particular, if anti-HER2 therapy is prescribed for non-HER2 positive 
patients (or if anti-HER2 therapy is not prescribed for HER2 positive patients), follow-up 
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Cost-Effectiveness Analysis of Fluorescence in Situ 
Hybridization and Immunohistochemistry for HER2 
Testing in Adjuvant Treatment of Breast Cancer 
 
4.1   Introduction 
 
Breast cancer is a leading cause of cancer-related deaths worldwide. However, rates of 
death from breast cancer are declining due to earlier detection and better treatment 
methods. (1)  One such treatment is trastuzumab (Herceptin®). It is a targeted therapy 
indicated for the treatment of breast cancers that exhibit HER2 amplification and/or 
protein overexpression. Accurate detection of HER2 status is critical for appropriate 
planning of breast cancer therapy since 20 to 30% of breast cancers are HER2 positive,  
and this is associated with increased tumor aggressiveness and poor prognosis (2 - 7).  
Testing for HER2 status is a topic of debate due to the issue of accuracy of available 
HER2 tests as well as the high cost of subsequent anti-HER2 therapy. In this study, we 
examine the cost effectiveness of FDA approved HER2 testing methodologies by 
considering test accuracy, health outcomes and financial costs. 
 
Trastuzumab has been shown to be cost-effective in the adjuvant treatment of HER2 
breast cancer. (8) Trastuzumab has significant benefits for HER2 positive breast cancer 
patients; however, it is associated with elevated risks of serious adverse events and with 
substantial costs.  While recent studies have determined some benefit of trastuzumab 
for HER2 negative patients, this requires further examination. (9) Current guidelines for 
treatment specify that tumor samples must be HER2 positive to receive benefit from 
trastuzumab. Therefore, to ensure appropriate use of this medication for breast cancer 





There are currently two main types of tests used to assess levels of HER2 in breast 
cancer: Fluorescence in Situ Hybridization (FISH) and Immunohistochemistry (IHC). 
FISH measures HER2 gene amplification while IHC measures levels of HER2 protein to 
determine if overexpression is present. There are six FDA-approved FISH and IHC tests 
for HER2 diagnosis in the United States: PathVysion (FISH, Vysis Inc.), INFORM (FISH, 
Ventana Medical Systems), FISH PharmDx (FISH, Dako), InSite (IHC, BioGenex 
Laboratories, Inc), HercepTest (IHC, Dako), and Pathway (IHC, Ventana).  
 
IHC and FISH vary in terms of cost and accuracy. A number of published reviews have 
evaluated HER2 testing. (10-27) These studies show high levels of variability with IHC 
results, while FISH is more reliable and serves as a gold standard for testing. (18-27) IHC 
protocols between laboratories vary in terms of the laboratory experience, score 
interpretations, and antibodies used for testing. (14-23) IHC for HER2 testing is scored on a 
scale from 0 (negative result) to 3+ (positive result). When IHC results are intermediate 
(indicated by a score of 2+), literature shows that they cannot be reliably used to 
determine a cancer’s HER2 status. (13, 19, 24-27) The strengths of IHC are that it is less 
expensive than FISH and it requires less laboratory personnel time and expertise. (15, 23) 
With regard to clinical outcomes, FISH testing is associated with better response rates 
with anti-HER2 therapy. (28-31)  
 
FISH is a more expensive test then IHC. The average cost per test has been reported to 
be approximately $482 for FISH versus $89 for IHC. (8)  The costs of performing the tests 
relative to effectiveness of the tests (e.g., the accuracy and value of results for IHC vs. 
FISH) determine the cost-effectiveness of HER2 testing.  However, few cost-




analyses are not in agreement. Based on their cost effectiveness analysis, Elkin et al. 
concluded that FISH should be the primary method for HER2 testing (32). In contrast, 
Falo et al. concluded that the ideal testing algorithm would involve using FISH only in 
those cases where FISH analysis is absolutely necessary and to use IHC (with both a 
monoclonal and polyclonal antibody) as the primary method for HER2 detection. (33)  In a 
study comparing FISH (using the Oncor/Ventana INFORM kit) and IHC (using a 
polyclonal antibody for HER2 detection) Jacobs et al. concluded that based on the high 
level of correlation (91%) between the two assays, the higher cost of FISH, and the 
longer times needed for this test, routine use of FISH is not justifiable. (34) Cost-
effectiveness studies which include the adverse health outcomes as well as financial 
costs involved in treating a patient falsely diagnosed as HER2-positive are needed in 
order to obtain a complete understanding of the two testing methods. The present study 
compares IHC and FISH while accounting for health and monetary costs associated with 
outcomes of unnecessary and potentially incorrect treatment. In addition, a no-test 
scenario where, hypothetically, all breast cancer patients are treated with trastuzumab is 
also presented for comparison.  
 
4.2   Materials and Methods 
 
Models for IHC, FISH, and No Test scenarios, complete with relevant testing costs and 
details of subsequent treatment and related health outcomes are modeled using 
TreeAge Pro Suite 2009 decision analysis software (figures 4.1-4.3). Deterministic 
analysis using point estimates and probabilistic sensitivity analysis using Monte Carlo 
simulations are performed in TreeAge. Costs of treatment and testing as well as 
probabilities for use in the models are obtained from literature. (8, 32, 35 - 38) We utilized 




and quantity of life years gained for a specific intervention. (39) They are widely used in 
health economics research because they provide a way to compare interventions across 
diseases; that is, this measure is not disease specific.  There are two main components 
to QALYS: a measure of quality of life (known as health utility) and a measure of life 
years gained (measured in years). A year in perfect health has a health utility value of 1, 
with other states having utility values between 0 and 1. (39) Death is considered to have a 
value of 0 for utility. (39) This utility value is multiplied by the number of years gained by 
the intervention in order to obtain a QALY value. We assume that the quality of life of 
patients on trastuzumab therapy does not vary significantly from the quality of life for 
patients on chemotherapy.  We made this assumption since in addition to responses 
from patients in the trastuzumab randomized trial, which found no significant differences 
between quality of life on chemotherapy and on trastuzumab therapy, an earlier study 
has also made this assumption. (32, 40-41) With this assumption and QALY estimates from 
previous studies, QALY values are assigned to the various branches in the models. We 
compared QALY values gained in each of the scenarios (No Test, IHC, FISH) in order to 
arrive at a conclusion regarding which strategy is most cost effective.  
 
The No Test model considers the scenario wherein neither FISH nor IHC are used for 
HER2 testing and all breast cancer patients are treated with adjuvant trastuzumab 
without HER2 testing (figure 4.1).  The IHC and FISH models consider a newly 
diagnosed breast cancer patient being tested for HER2 (with either IHC or FISH; figures 
2 and 3). Numerous studies have established that 20 – 30% of breast cancers are HER2 
positive, and this is reflected in both models as the Actual HER2+ rate. (2-7) The 
sensitivity and specificity of the tests are reflected as true positive and true negative 
rates in the figures.  Depending on the outcome of the test, the patient is offered 




results (true positives and false positives) undergo anti-HER2 treatment with 
trastuzumab in addition to chemotherapy, but some do not, as shown in the model. The 
probability of receiving trastuzumab therapy based on HER2 test results was computed 
using a data-set containing information on breast cancer patients, testing, and treatment 
(provided by the American Cancer Society; collected by Rabbit Health Systems, Austin, 
TX). Data was collected from six outpatient oncology clinics located across the United 
States. Out of 746 patients considered from this data-set, 199 were HER2 positive and 
140 were HER2 positive and treated with trastuzumab. Therefore, patients who are 
found to be HER2+ have a probability of 0.7 of being treated with trastuzumab. This is 
shown in figures 4.2 and 4.3 under the “Trastuzumab” treatment branches for true and 
false positives. Treatment with trastuzumab carries risk of adverse cardiac-related side 
effects which is also incorporated into the model. Recurrence rates for each branch of 
treatment are shown in the model as obtained from literature. (8, 35) 
 
Costs associated with each stage of testing, treatment and management of disease are 
incorporated into the model. With respect to HER2 testing, the cost of FISH is $482 per 
test while IHC costs $89 per test. (8) With regard to treatment, the cost of trastuzumab 
therapy is $126511, in addition to the cost of chemotherapy. All patients are assumed to 
receive some form of therapy (i.e., chemotherapy, radiation or surgery) either alone or in 
addition to trastuzumab. Treatment with chemotherapy, radiation or surgery alone is 
estimated at $31,149. (8, 36) The cost of treatment for recurrent and non-recurrent disease 
as well as the cost of management for cardiac dysfunction associated with trastuzumab 
are included in the model and are based on estimates from previous analyses. (8, 37) 
 
Monte Carlo simulations are used to analyze the effect of uncertain parameters in the 




effect of varying false positive and false negative probabilities on the overall model. 
Numerous studies have established that IHC false positives are a major source of 
variability when using this test for HER2 and that these rates vary with the particular IHC 
test that is selected for use. (3, 16, 18-19, 24, 42-44) Therefore, understanding how the IHC 
model performs under varying false positive probability is of interest. The Beta 
distribution, a continuous probability distribution, lends itself well to modeling 
probabilities as it is defined in the interval [0, 1]. In this analysis, for both the FISH and 
IHC trees, the false positive probability is varied using a Beta distribution to model the 
probability values, and the associated α and β values for this distribution are assigned 
using the expected value for the variable obtained from literature. (32) 
 
Figure 4.1: No HER2 Test Scenario  
 
Key:  
• CSR + TRAS for BC = Chemotherapy/Surgery/Radiation with Trastuzumab for Breast 
Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 




Figure 4.2: IHC for HER2 Testing in Breast Cancer – A Model 
 
Key:  
• IHC for BC = Immunohistochemistry for Breast Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 












• FISH for BC = Fluorescence In Situ Hybridization for Breast Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 










Similarly, the false negative probability is modeled using a Beta distribution.  
The input distributions are shown in figures 4.4-4.5. Monte Carlo probabilistic sensitivity 
analysis is applied in order to determine the behavior of the model under these 
parameter uncertainties. 
 
Figure 4.4a: Input Beta Distribution for IHC False Negatives  
 
Key:  
• Beta distribution: α = 8, β = 92, Expected Value = 0.08 
 
Figure 4.4b: Input Beta Distribution for IHC False Positives 
 
Key:  












• Beta distribution: α = 5, β = 95, Expected Value = 0.05 
 
 











The disease states described in the decision trees above may be modeled using a 
Markov model (figure 4.6). Such a model shows the various possible states that a 
patient with an initial breast cancer diagnosis may enter, depending on the course of 
testing and treatment that is undertaken. Patients may move in allowed paths between 
certain states based on transition probabilities which are specified in the decision trees.  
 
 








• BC = Breast Cancer 
• HER2+ Recurrent = Actual HER2+ breast cancer that recurs 
• HER2+ Non-recurrent = Actual HER2+ breast cancer that does not recur 
• HER2- Recurrent = Actual HER2- breast cancer that recurs 

















4.3   Results 
 
The No Test, IHC, and FISH models are shown in figures 4.1 – 4.3.  A description of the 
results using probabilistic sensitivity analysis follows that using point estimates. The 
analyses show that the FISH model dominates both the IHC and No Test models and is 
the cost effective technique for HER2 testing in breast cancer.  
4.3.1   Point Estimate Analysis 
 
The expected cost of the No-test model based on the specified costs and probabilities is 
$166,360 (figure 4.7). The expected cost of HER2 testing and treatment per patient with 
IHC, taking into account the probabilities of various scenarios and costs associated with 
trastuzumab therapy, chemotherapy, radiation and surgery is $72,405 (figure 4.8). A 
similar rollback for FISH shows that the expected cost of testing and treatment when 
FISH is used for HER2 testing in breast cancer is $64,626 per case (see figure 4.9). 
Considering QALYs, the expected value of total QALYs gained from IHC testing (and 
subsequent treatment) and FISH testing (and subsequent treatment) are 11.63 and 
11.64 respectively. While the expected cost of FISH testing and treatment is lower than 
IHC testing and treatment, the expected QALYs are higher with FISH (by 0.01 QALY). 
Therefore, with FISH, there is a gain in QALYs for less cost than with IHC. From a cost 
effectiveness perspective, FISH testing clearly dominates IHC since it costs less money 
and provides more health benefit than IHC. The No Test scenario is ruled out by 
extended dominance, since the incremental cost effectiveness ratio of this strategy 
(when compared to FISH) is $726,671, well above all accepted thresholds of cost-
effectiveness. (45 - 46)  A commonly used threshold is $50,000: Interventions that cost less 
than $50,000 per QALY gained are considered cost effective. This number comes from 




QALYS is that this threshold value has not changed and has been arbitrarily assigned as 
a determination of society’s willingness to pay for interventions. (46) Though many believe 
it should be higher than $50,000, the No Test scenario would fall well above all proposed 
thresholds. 
 
Assuming that that knowledge of disease state does not detract from QALYs, the ideal 
scenario for HER2 positive patients would be a true positive result on the HER2 test 
since this would enable appropriate treatment planning and minimize chance of 
recurrence.  Being in this state provides the opportunity for appropriate treatment with 
trastuzumab and the highest QALY-payoff (11.78, which is the same number of QALYs if 
the patient was actual HER2 negative). The probability of being true positive is 0.033 
greater if tested with FISH; i.e. there is a 3.58% percentage probability increase that a 
patient who is true HER2 positive will be diagnosed as positive if tested with FISH rather 
than IHC. Put another way, considering the entire path to reach trastuzumab treatment, 
the probability of reaching this node (Actual HER2+ > True + > Trastuzumab) is 
0.16695 with FISH (0.25 * 0.954 * 0.3) while it is 0.161175 for IHC (0.25 * 0.921 * 0.7). 
Therefore, the probability increase that a person with breast cancer will arrive at this 
node is 0.006 greater if tested with FISH rather than IHC, which represents a 3.58 
percentage probability increase. The expected value of cost at the true positive node for 
IHC is $135560 while for FISH it is $135943, a difference of $383.  
 
For HER2 negative patients, the ideal scenario would be a true negative result where the 
QALYS are 11.78. While QALYS remain the same for all HER2 negative patients, 
whether or not they are treated with trastuzumab, the cost of treatment varies 




probability of being true negative is higher than with IHC, this time with a larger margin 
(0.132). There is a 15.66 percentage probability increase that a patient who is HER2 
negative will be diagnosed as negative if tested with FISH rather than IHC.  
 
From a patient perspective, the worst case scenario is being HER2 positive and being 
diagnosed as HER2 negative since this reduces the likelihood of being treated with 
trastuzumab significantly and increases the possibility of recurrence. This in turn 
increases the risk of having lower QALYs than if correctly diagnosed. The likelihood of 
this situation is greater with IHC, with HER2 positive patients having 0.079 probability of 
being tested as negative, while the same probability for FISH cases is a lower 0.046.  
 
From a cost-perspective, the worst case scenario is treatment with trastuzumab when 
there is no established benefit from this treatment. QALYS remain at 11.78 years for all 
patients who are HER2 negative, but there is a significant increase in cost for those who 
are treated with trastuzumab. This particular scenario occurs when HER2 negative 














Figure 4.7: No Test Scenario – Expected Values 
 
Key:  
• CSR + TRAS for BC = Chemotherapy/Surgery/Radiation with Trastuzumab for Breast 
Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 
• Values below branches are probabilities 



















• IHC for BC = Immunohistochemistry for Breast Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 
• Values below branches are probabilities 











• FISH for BC = Fluorescence In Situ Hybridization for Breast Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 
• Values below branches are probabilities 









The false positive probability of IHC is significantly higher than that of FISH (0.157 for 
IHC vs. 0.025 for FISH); i.e., with respect to IHC, there is an 84.07 % decrease that a 
patient who is HER2 negative will be diagnosed as positive if tested with FISH. 
 
Overall, the expected value of the Actual HER2 Negative node is less for FISH than IHC 
(by a value of $11321), due to the increased probability of being incorrectly treated with 
trastuzumab with IHC. The expected value of the Actual HER2 Positive node is higher 
for FISH (by $2842) due to higher likelihood of correct trastuzumab treatment (which is 
significantly more expensive than chemotherapy, radiation or surgery). Combining both 
situations, and their associated probabilities, the total expected value of using FISH for 
HER2 testing in breast cancer is $64,626 and the total expected value for IHC is higher 
at $72,405. 
  
4.3.2   Probabilistic Sensitivity Analysis  
 
The point estimate analysis described previously considers the IHC and FISH models 
under deterministic conditions where all parameters were assigned specified point 
values that were not varied. In this part of the analysis, we consider the effect of 
uncertainty in the model, and present results if certain parameters, specifically the false 
positive and false negative probabilities, behaved as probabilistic elements. Monte Carlo 
simulation is utilized to compute expected values using these uncertainties. The 

















• IHC for BC = Immunohistochemistry for Breast Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 
• Values below branches are probabilities 
• # indicates probability of branch determined by distribution value assigned to 
complementary branch 
• Global distribution declarations shown at root node: 
1. IHC_False_Neg_Dist: Beta distribution, α = 8, β  = 92, Expected Value = 0.08 




Figure 4.11: FISH Model for Probabilistic Sensitivity Analysis  
 
Key:  
• FISH for BC = Fluorescence In Situ Hybridization for Breast Cancer 
• QALYs  = Quality Adjusted Life Years associated with the nearest node to the right of box 
• Payoff values at terminal nodes are in dollars 
• Values below branches are probabilities 
• # indicates probability of branch determined by distribution value assigned to 
complementary branch 
• Global distribution declarations shown at root node: 
1. Dist_FISH_False_Negatives: Beta distribution, α = 5, β  = 95, Expected Value = 0.05 







The Monte Carlo simulation is run through 100000 iterations of the model (for both the  
IHC and FISH models). The simulation is run at the root node (IHC for BC and FISH for 
BC in figures 4.10 and 4.11). The comparative summary of Monte Carlo simulation 
results for IHC and FISH is shown in Table 4.1. In addition to one Monte Carlo run with 
100000 iterations, 30 additional runs were completed to provide a better estimate of the 
values in table 4.1. 
 
Table 4.1: Monte Carlo Probabilistic Sensitivity Analysis Results for IHC and FISH 
 
Statistic IHC Single Run 
Value 
IHC Multi Run 
Average 
 
FISH Single Run 
Value 
FISH Multi Run 
Average 
 
Mean  $72591 $72587 $64881 $64884 
Std Dev $2474 $2478 $1195 $1199 
Minimum $64093 $64240 $61173 $60991 
2.5% $68156 $68151 $63026 $63021 
10% $69526 $69499 $63529 $63534 
Median $72449 $71480 $64710 $64709 
90% $75848 $75816 $66468 $66476 
97.5% $77820 $78190 $67680 $67698 
Maximum $84327 $85482 $73093 $73428 










The distribution of outcomes for 100000 iterations of the Monte Carlo simulation is 
shown in Figure 4.12 for IHC and Figure 4.13 for FISH. 
 
Figure 4.12: Distribution of Outcomes for IHC Simulation (at Root Node) 
 
 






From Table 4.1, we see that the cost of testing and treatment with IHC is higher than 
FISH at all major statistical sampling levels. For example, the minimum value of the cost 
of testing and treatment with IHC testing for HER2 is greater than corresponding 
scenario with FISH by $2920 (table 4.1, single run comparison). When probabilistic 
sensitivity analysis is performed at the Actual HER2- node of the IHC model, the value is 
$53,577 as compared with $42,429 for the same node on the FISH tree. The higher 
expected value of false positives for IHC increases the cost of treatment of actual HER2 
negative patients, which drives up the overall cost with IHC. On an average, the cost of 
testing and treatment with IHC is $7710 greater than the cost of testing and treatment 
with FISH. The range of outcomes is also wider for IHC (figures 4.12 and 4.13) indicating 
that the costs of FISH are more concentrated around the expected mean value. 
 
The cost of IHC approaches the mean cost of FISH at the minimum value on the IHC 
cost curve (table 4.1, figures 4.12 and 4.13). At that point, the values of the false positive 
probability and false negative probability for IHC are 0.046 and 0.011 respectively.  In 
order for IHC to become competitive with FISH, the false positive probability would have 
to decrease by over 80%. Similarly, the false negative probability of would have to 
decrease by 37.5%.  
 
4.4   Discussion 
 
FISH dominates IHC and No Test in terms of cost effectiveness. From the point estimate 
and the probabilistic sensitivity analyses discussed above, it is clear that although FISH 
by itself is a more expensive test, the overall cost of FISH testing and subsequent 
treatment is typically lower than the overall cost of IHC testing and subsequent 




trastuzumab, which thereby leads to gain in QALYs. A detailed look at each model 
shows that FISH is more advantageous to use than IHC in all scenarios. At every single 
chance node, FISH testing provides a higher probability of being detected and treated 
correctly. In certain nodes (as with false positive cases), using IHC provides a distinct 
cost disadvantage that is several thousand dollars large, and ending up on this route is 
much more likely using IHC. In other words, when the FISH route costs more by a few 
hundred dollars (at maximum), it always results gain of QALYs, while when the IHC 
route costs more (at several thousand dollars on average) there is no health benefit 
associated with the cost. With regard to adverse health outcomes, the probability of not 
receiving trastuzumab for HER2 breast cancer as indicated by the FDA is decreased if 
tested with IHC. This situation is of particular concern due to the reduced quality of life 
and increased chance of recurrent disease with HER2 breast cancer that is not treated 
with anti-HER2 therapy.  In addition, the high false positive probability of IHC puts 
patients at a higher risk of being diagnosed as HER2 positive (when actual HER2 
negative). This in turn increases the risk of these patients developing trastuzumab-
induced cardiac dysfunction.  
 
In this study, we did not evaluate the cost-effectiveness or clinical efficacy of 
trastuzumab treatment, as this has been established by previous studies. (8, 47-48) This 
analysis focused on the cost effectiveness of FISH and IHC testing methods as ways to 
detect HER2 positive breast cancers, and subsequent treatment with trastuzumab, 
chemotherapy, radiation or surgery.  From the findings in this study, we believe that if 
trastuzumab therapy is cost-effective and clinically beneficial to patients in terms of 
health outcomes, then FISH should be the only method of HER2 testing used. The 
benefits of using FISH overwhelmingly outweigh the $393 monetary benefit of IHC being 





The reasons for FISH being the better alternative for HER2 testing are two-fold: 
1. Higher costs of FISH are outweighed by the significantly higher accuracy rates of 
FISH testing, especially considering the enormous cost of trastuzumab 
treatment. That is, FISH testing increases the likelihood that trastuzumab is given 
to patients who will receive QALY benefit from it.  
2. The high false positive probability of IHC testing dilute the cost advantage of this 
test since incorrect treatment with trastuzumab is an additional cost of $126511 
per patient when compared to the $393 savings from using IHC instead of FISH. 
Treating false positive patients with trastuzumab provides no QALY gain.  
 
When the sensitivity and specificity rates are varied and costs are computed, the 
financial advantages of using FISH become clearer. From Table 4.1, it is evident that the 
cost of FISH and associated treatment for breast cancer is lower than IHC in all sampled 
scenarios at varying levels of specificity and sensitivity. In fact, even if IHC had no 
monetary cost (i.e., if IHC cost = $0), FISH would still be the more cost-effective. This is 
because the cost of IHC and FISH are small when compared to the cost of treatment 
with trastuzumab. FISH enables appropriate treatment with this drug, and being tested 
with FISH decreases the likelihood that persons who do not require the drug receive it. 
Therefore, we see significant cost savings with FISH despite the test itself being a few 
hundred dollars more expensive than IHC. For IHC to be competitive with FISH, the test 
would have to have become more accurate by improving specificity and sensitivity. The 
required improvement in false positive and false negative probabilities for IHC is 80% 
and 37% respectively. While it is possible that with automated image analysis, better 
quality assurance techniques in laboratories and increased standardization of 




false negative probabilities could decrease as significantly as required or if the cost and 
time associated with making these improvements is worth the effort. 
 
Considering health outcomes and financial costs, FISH is a more cost-effective method 
than using IHC for HER2 testing in breast cancer. We recommend the use of FISH for all 
breast cancer cases in order to improve clinical outcomes as well as reduce overall 
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Knowledge of the existence of differences in the care of HER2 breast cancer is a 
fundamental step toward understanding if these differences are based on sound clinical 
reasoning or if there is a need to reduce and ultimately eliminate these differences. In 
this research, we found that geographic location, cancer stage (specifically, the T stage) 
and time of diagnosis (before or after 2001) have significant effects on the choice of 
HER2 test. With respect to location, we found patients in Central Texas, South Texas 
and Los Angeles sites are significantly more likely to be tested with FISH than those in 
South Dakota.  Our analysis also showed that patients who have in situ tumors are 
significantly less likely to be tested with FISH than those with advanced T stage disease. 
Finally, with respect to HER2 testing, we found that patients tested before publication of 
the 2001 testing guidelines were less likely to be tested with FISH than those diagnosed 
after guideline publication.  These results highlight the importance of testing guidelines, 
show that physicians currently test conservatively, with the older and less expensive 
test, and reveal the existence of possible disparities in HER2 testing based on location.  
 
We also analyzed the effects of clinical and non-clinical factors on the prescription of 
anti-HER2 therapy with trastuzumab. We found that patients treated in the South Texas 
site were less likely to receive trastuzumab treatment when compared to patients in the 
South Dakota site. We also found that HER2 positive patients are significantly more 
likely to receive trastuzumab than HER2 negative or HER2 unknown patients. These 
results reveal the existence of possible disparities due to location in the use of 




HER2 positive patients (as currently required for receipt of trastuzumab), patients with 
other HER2 statuses (negative/unknown) also receive this drug even though the clinical 
benefit for this group of patients using trastuzumab has not been established. 
 
Cost of testing and treatment for HER2 breast cancer is a topic of significant debate. The 
choice of test plays a critical role in determining suitable candidates for anti-HER2 
therapy. Since much of the debate in this field is due to the difference in price between 
the two methods used for HER2 testing and the high cost of trastuzumab treatment, we 
analyzed the overall cost effectiveness of IHC and FISH by including costs of 
subsequent treatment. We showed that FISH is the best choice for HER2 testing since it 
is both lower in cost per QALY gained (when testing and subsequent treatment are 
considered together) and is associated with better response to trastuzumab in terms of 
clinical outcomes. The high false positive rate of IHC drives down the cost effectiveness 
of this test by over-selecting patients for trastuzumab treatment, and makes it unsuitable 
for use in HER2 testing. Although IHC is less expensive than FISH and takes less time 
to complete, these advantages are outweighed by the lower accuracy levels of the test. 
The improvements required to make IHC competitive with FISH are significant and 
unlikely to occur in the short term.  
 
Certain limitations of this study may have potentially prevented other significant effects 
from being reported, specifically with regard to the analyses dealing with factors 
influencing HER2 testing and treatment. For example, the effect of insurance status on 
trastuzumab prescription was seen as a non-significant trend, likely due to the small 
sample size included for analysis. Also, certain kinds of data were unavailable for 
analysis. For example, socio-economic and race data were unavailable and therefore 




each outpatient clinic was also not provided in the data-set. It is likely that inclusion of 
such factors into this analysis will add to our knowledge regarding the cause of existing 
disparities.   
 
The next steps in this research area involve gaining a deeper understanding of the 
clinical and non-clinical factors that affect HER2 testing and treatment. Specifically with 
regard to HER2 testing, the value (if any) of HER2 testing for in situ tumors needs to be 
determined, in addition to the role of socioeconomic and race issues in this medical 
decision making process. With regard to anti-HER2 therapy, the role of patient behavior 
in terms of refusal to begin therapy or failure to adhere to therapy could provide insight 
into why trastuzumab is not prescribed for all HER2 positive patients. In addition, the 
interaction of treatment patterns with age, race, and socio-economic factors needs to be 
considered and analyzed.  The value (if any) of trastuzumab therapy  for HER2 negative 
patients requires further examination and if clinical benefit is established, an overhaul of 
current testing and treatment patterns would be required.  
 
In summary, this research utilized Electronic Medical Record (EMR) data from patients 
diagnosed with breast cancer in the United States to determine if any significant 
associations exist between various factors and HER2 testing and treatment. In addition, 
we also analyzed the cost effectiveness of FISH vs. IHC testing in HER2 breast cancer. 
Our results show that disparities exist in the care of HER2 breast cancer and that FISH 
is the best choice for HER2 testing among currently approved FDA tests.  
